Betta Non Currrent Assets Other from 2010 to 2024

300558 Stock   52.69  1.11  2.06%   
Betta Pharmaceuticals' Non Currrent Assets Other are decreasing over the years with slightly volatile fluctuation. Non Currrent Assets Other are expected to dwindle to about 15.7 M. Non Currrent Assets Other is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. View All Fundamentals
 
Non Currrent Assets Other  
First Reported
2019-03-31
Previous Quarter
876.9 K
Current Value
664.6 K
Quarterly Volatility
174.3 M
 
Covid
Check Betta Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Betta Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 32.1 M, Selling General Administrative of 632.6 M or Total Revenue of 1.4 B, as well as many indicators such as . Betta financial statements analysis is a perfect complement when working with Betta Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Betta Pharmaceuticals Technical models . Check out the analysis of Betta Pharmaceuticals Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Betta Stock

Betta Pharmaceuticals financial ratios help investors to determine whether Betta Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Betta with respect to the benefits of owning Betta Pharmaceuticals security.